



July 24, 2014

Acura Pharmaceuticals to Host Second Quarter 2014 Financial Results Conference Call on August 5, 2014

PALATINE, IL -- (Marketwired) -- 07/24/14 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating [abuse deterrent drugs](#), today announced that the Company plans to report financial results for the second quarter 2014 following the close of financial markets on Monday, August 4, 2014. The Company will host a conference call to discuss the results on Tuesday, August 5, 2014 at 8:30 a.m. ET.

To participate in the live conference call, please dial **1-888-505-4369** (U.S. and Canada) five to ten minutes prior to the start of the call. The participant passcode is **8612011**. A replay of the call will be available beginning August 6, 2014 at 11:30 a.m. ET and ending on August 22, 2014 on the company's website, and by dialing **1-888-203-1112** (U.S. and Canada). The replay participant code is **8612011**.

About Acura Pharmaceuticals

Acura Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development and commercialization of product candidates intended to address medication abuse and misuse, utilizing its proprietary AVERSION® and IMPEDE® Technologies. AVERSION® contains polymers that cause the drug to gel when dissolved; it also contains compounds that irritate the nasal passages. IMPEDE® is designed to disrupt the processing of pseudoephedrine from tablets into methamphetamine.

In June 2011, the U.S. Food and Drug Administration approved our oxycodone HCl immediate-release tablets which incorporate the AVERSION® Technology. The Company has a development pipeline of additional AVERSION® Technology products containing other opioids.

In December 2012, the Company commenced commercialization of NEXAFED® [pseudoephedrine hydrochloride (HCl)], a 30 mg immediate-release abuse-deterrent decongestant. The next generation pseudoephedrine tablet combines effective nasal congestion relief with IMPEDE® Technology, a unique polymer matrix that disrupts the conversion of pseudoephedrine into the dangerous drug, methamphetamine.

Contact:

for Acura Investor Relations

[Email Contact](#)

847-705-7709

for Acura Media Relations

[Email Contact](#)

847-705-7709

Source: Acura Pharmaceuticals, Inc.

News Provided by Acquire Media